You just read:

Avanir Pharmaceuticals Initiates Phase II Study to Evaluate AVP-786 for Treatment of Neurobehavioral Disinhibition Associated with Traumatic Brain Injury

News provided by

Avanir Pharmaceuticals, Inc.

Jun 07, 2017, 09:00 ET